Searched for
PHARMACEUTICAL EXPENDITURE
Strong balance sheets help India Inc absorb West Asia fallout: CrisilA stress test by Crisil Ratings covering 34 sectors that account for 65% of its rated corporate debt suggests that India Inc remains broadl...- Forget power: The unquenchable AI thirst propelling water stocks up to 45%India's water sector is experiencing a surge, with stocks like Shakti Pumps and VA Tech Wabag jumping up to 45% in a month. This rally is f...
- Banking, capital goods and midcaps seen driving market's next rally: Ashish ChaturmohtaIndian equities are poised for fresh highs, driven by strong earnings and sector-specific momentum, particularly in financials and manufact...
- Falling crude, stronger rupee could boost earnings outlook for India: Deepak ShenoyIndian stocks are poised for a favorable period. Falling crude oil prices and a strengthening rupee offer support. Macroeconomic conditions...
- Why a Rs 72,000 crore fund manager refuses to chase defence rally nowICICI Prudential's Mittul Kalawadia advises caution on current market valuations. He notes that future growth is already factored into stoc...
- India's productivity gap with China widens despite strong GDP growth; manufacturing leap still missing: ReportIndia's labour productivity gap with China has widened significantly since 2000, despite strong economic growth. The country has yet to ach...
- Over 60% of pharma MSMEs yet to comply with updated manufacturing normsPharma industry officials say the revised Schedule M regulations could require Rs 10-15 crore per facility in upgrades, while talent shorta...
- From Adani Green to Tata Tech: 50 companies swing back to profit in Q4 despite market turmoilIndian companies show strong recovery. Over 50 firms moved from losses to profits in the March quarter. This turnaround happened despite ma...
- Out-of-pocket expenditure share declines by 21 percentage points from 2013-14: Health ministryGovernment health spending has risen, leading to a significant drop in out-of-pocket health expenses. This decline, from 64.2% in 2013-14 t...
- Margin pressure, slower growth outlook may cap upside for Sun Pharma stockSun Pharma reported strong revenue and profit growth in the March quarter, but EBITDA margins faced pressure from increased investments and...
- June quarter earnings to determine market direction, says Sunil Subramaniam, warns on risks in near termMarket expert Sunil Subramaniam advised caution amid geopolitical uncertainty and rising input costs, while favouring consumer durables, ca...
- Sun Pharma Q4 Preview: Can Unloxcyt and speciality drugs help pharma major deliver another strong quarter?Sun Pharma is expected to post double-digit revenue growth in Q4FY26, driven by strong performance across speciality drugs, domestic formul...
- Bio Medica Laboratories IPO: Check GMP, price band, subscription and other detailsBio Medica Laboratories' initial public offering begins subscription on Thursday. The company plans to raise Rs 52.43 crore through its IPO...
- India needs to raise R&D spending to 2 pc of GDP by 2035 to boost manufacturing: ReportIndia's manufacturing growth is hampered by low R&D spending, currently at 0.6% of GDP, a report highlights. To boost its manufacturing sha...
- Want to jump into the 'China is back' rally? Tread carefullyInvestors are increasingly betting that “China is back” as the economy rebounds from years of deflation, helped by strong manufacturing, ex...
- Delhivery elevates six executives to C-suite roles amid expansion pushLogistics firm Delhivery has promoted six senior executives to C-suite positions. These appointments support the company's expansion across...
- Nifty to hit 42,000 by 2028? New paper that studied market cycles says it's possible if these factors alignA CNI InfoXchange study projects the Nifty could surpass 42,000 by 2028 if sustained foreign investor inflows return. The report highlights...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- IPO Calendar: 2 issues to keep investors busy but mainboard activity remains mutedIndia's primary market is set for a busy week with two SME IPOs. RFBL Flexi Pack and Goldline Pharmaceutical will open for subscription on ...
- Compliance squeeze, global scrutiny redefine India’s $30 billion pharma export playbookAs global markets prioritise quality and regulatory trust, India’s pharma sector is recalibrating beyond its traditional cost advantage.
Load More
